[go: up one dir, main page]

EP2125062A2 - Système expansible muni d'un revêtement - Google Patents

Système expansible muni d'un revêtement

Info

Publication number
EP2125062A2
EP2125062A2 EP08706903A EP08706903A EP2125062A2 EP 2125062 A2 EP2125062 A2 EP 2125062A2 EP 08706903 A EP08706903 A EP 08706903A EP 08706903 A EP08706903 A EP 08706903A EP 2125062 A2 EP2125062 A2 EP 2125062A2
Authority
EP
European Patent Office
Prior art keywords
stent
acid
inflammatory
poly
catheter balloon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08706903A
Other languages
German (de)
English (en)
Inventor
Michael Orlowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eurocor GmbH
Original Assignee
Eurocor GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurocor GmbH filed Critical Eurocor GmbH
Publication of EP2125062A2 publication Critical patent/EP2125062A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08—Materials for coatings
    • A61L29/10—Inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow

Definitions

  • the present invention relates to an expandable catheter balloon catheter system having a crimped stent, which system combines rapid release kinetics of one drug with a slow release kinetics of a second drug, as the catheter balloon with a first drug suitable for rapid release and the stent with a second drug suitably coated for a slower release.
  • restenosis i. the reclosure of the vessel.
  • PTA percutaneous transluminal angioplasty
  • Restenosis after stenting is one of the main causes of hospitalization.
  • the vascular injuries caused during implantation of the stent cause inflammatory reactions that play a crucial role in the healing process in the first seven days.
  • the processes involved in this process are associated, inter alia, with the release of growth factors, whereby an increased proliferation of smooth muscle cells is initiated and thus already in the short term lead to restenosis, a re-occlusion of the vessel due to uncontrolled growth.
  • the present invention is based on the observation that the extent and occurrence of restenosis in particular be determined by the first week after stent implantation and it is therefore of particular importance to treat inflammations as well as possible during these approximately first 7 days after stent implantation.
  • Object of the present invention is to provide a system which provides a full-surface supply of stenosed tissue with a drug in high Concentration immediately after dilation and a low drug supply ensured some time after dilatation.
  • the present invention discloses an expandable system of a catheter balloon having an attached crimped stent with an active agent having a release kinetics other than that on the stent on the catheter balloon.
  • the catheter balloon is preferably coated over its entire surface with an active ingredient.
  • active ingredient refers in particular to the anti-proliferative, antiinflammatory, antiangiogenic, cytostatic, cytotoxic, antithrombotic, antiinflammatory and / or antiestrogenic active ingredients mentioned further below.
  • full-area coating means that the catheter balloon is coated over its entire length, which can also extend beyond the length of the stent and thus can provide the constricted vessel segment over the entire surface with active ingredient.
  • drug can only be delivered from the stent to the immediately adjacent tissue.
  • drug is delivered from the stent and also from the catheter balloon in the spaces between the stent struts in the expanded state.
  • another active substance can be present on the catheter balloon than on the stent, but the same active substance can also be used on the catheter balloon and the stent in different concentrations.
  • a first active ingredient and “a second active ingredient” refer to at least two different active substances or to the same active ingredient in two different concentrations.
  • at least two agents means that there are two or more agents on the catheter balloon and on the stent one or more drugs, or two or more drugs on the stent and one or more drugs on the catheter balloon.
  • the expandable system preferably has a combination of two drugs with different release kinetics or only one drug in two different concentrations and with different release kinetics.
  • the at least one active substance is dispensed from the catheter balloon more quickly or quenched or transferred to the vessel wall than the at least one active substance on the stent.
  • the release rate of the at least one drug on the stent should therefore be slower than the release rate of the at least one drug on the catheter balloon.
  • the rate of release of the at least one drug on the catheter balloon is such that at least 10% by weight of the amount of drug on the catheter balloon is within one minute, preferably within 45 seconds, more preferably within 30 seconds, and especially preferably be delivered within 20 seconds, with delivery preferably being understood to mean the transfer to the vessel wall.
  • release kinetics are referred to a period of 30 seconds, preferably 5% by weight, more preferably 10% by weight, even more preferably 15% by weight and especially preferably 20% by weight of the Delivered drug on the catheter balloon at the time of dilation, with delivery preferably being understood to mean the transfer to the vessel wall.
  • a molar amount of active ingredient is applied to the catheter balloon 5 times higher, preferably 10 times higher, more preferably 20 times higher, and most preferably 30 times higher than on the stent.
  • the expandable system of the present invention provides a combination of catheter balloon and stent capable of providing a combination therapy with two drugs or with one drug at different concentrations.
  • the system according to the invention can also be provided in two variants, namely an embodiment with a biostable stent and an embodiment with a bioresorbable stent.
  • a stent made of the usual, preferably metallic materials is used.
  • non-bioresorbable means that the stent is a permanent implant that is not or only slowly dissolves under physiological conditions
  • stents are for example made of medical grade stainless steel, titanium, chromium, vanadium, tungsten, molybdenum, gold, nitinol, Magnesium, zinc, alloys of the aforementioned metals and ceramics or biostable polymers.
  • biodegradable or biodegradable stent a stent of a biodegradable metal alloy or a biodegradable polymer is used, which stent may be coated with a pure drug layer and / or in the biodegradable material itself can be introduced or stored one or more drugs and / or the bioresorbable stent may be coated with a biodegradable coating containing one or more active substances.
  • This variant offers an ideal system a severely narrowed body passage such as bile ducts, esophagus, urinary tract, pancreas, Renal, pulmonary, trachea, small intestine and colon, and in particular to keep open blood vessels with a permanent stent, which preferably has a coating with a cytostatic dose of an active ingredient.
  • the catheter balloon according to this variant is coated with a pure drug layer or a carrier containing an active ingredient and dilation on the one hand, the stent set and on the other at least over the entire length of the stent and advantageously even moreover applied an active ingredient for a Controlled ingrowth and prevention of overgrowth of the stent with especially smooth muscle cells provides.
  • active substance or active substance mixture the below-mentioned active substances and in particular Paclitaxel and / or Rapamycin can be used.
  • the catheter balloon is coated with drug with or without a carrier system such that the balloon coating extends beyond both stent ends and preferably extends beyond 10-20% of the total length of the stent beyond an end of the stent.
  • the active ingredient is also on the catheter balloon
  • the stent surface has an active substance which, however, preferably does not kill the smooth muscle cells but only inhibits their growth and thus does not kill cells which directly communicate with the stent surface.
  • enough active substance is applied to the intermediate spaces between the stent struts and also at the ends or in the two areas beyond the stent ends of the vessel wall, so that the too rapid overgrowth of the stent, which begins in the interstices of the stent struts and begins in the Inside the stent continues and leads to in-stent restenosis, is contained or reduced to a controlled level.
  • a drug-coated stent emits the active substance only from its surface and not from the interstices of the stent struts or at the ends of the stent or beyond and moreover just to the adjacent tissue, which is not to be inhibited or killed, according to This variant of the active ingredient applied exactly where it is needed.
  • the catheter balloon is coated with the drug with or without carrier and then a coated stent is crimped onto the balloon.
  • Suitable carrier systems for the drug on the catheter balloon as well as on the stent are described in more detail below.
  • bioresorbable stent The embodiment with a bioresorbable stent will probably become more important in the future, since this embodiment does not represent a permanent implant.
  • This embodiment uses biodegradable, i. bioresorbable stents. Such degradable stents under physiological conditions are completely degraded in the patient's body within a few weeks to one or two years.
  • Biodegradable stents consist of metals such as magnesium, calcium or zinc or of organic compounds such as polyhydroxybutyrate, chitosan or collagen.
  • a bioresorbable metal stent consisting predominantly of magnesium is disclosed in European patent EP 1 419 793 B1.
  • the German Offenlegungsschrift describes stents made of magnesium alloys and zinc alloys.
  • Bioresorbable stents made of magnesium, calcium, titanium, zirconium, niobium, tantalum, zinc or silicon or of alloys or mixtures of the abovementioned substances is disclosed in German Offenlegungsschrift DE 198 56 983 A1.
  • Explicit examples are disclosed in zinc-calcium alloy stents.
  • a biodegradable stent of the organic compound polyhydroxybutyrate (PHB) and other polyhydroxyalkanoates is disclosed in U.S. Patents US 6,548,569 B1, US 5,935,506, US 6,623,749 B2, US 6,838,493 B2 and US 6,867,247 B2.
  • US Pat. No. 6,245,103 B1 also mentions polydioxanones, polycaprolactones, polygluconates, polylactic acid-polyethylene oxide copolymers, modified cellulose, Collagen, poly (hydroxybutyrate), polyanhydrides, polyphosphoesters and polyamino acids as further suitable biodegradable stent materials.
  • biodegradable stents can be produced from the following substances or mixtures of the following substances: polyvalerolactones, poly- ⁇ -decalactones, polylactides, polyglycolides, copolymers of polylactides and polyglycolides, poly- ⁇ -caprolactone, polyhydroxybutyric acid, polyhydroxybutyrates, polyhydroxyvalerates, polyhydroxybutyrate-co-valerates , Poly (1,4-dioxane-2,3-dione), poly (1,3-dioxan-2-one), poly-para-dioxanone,
  • Polyanhydrides such as polymaleic anhydrides, polyhydroxymethacrylates, fibrin, polycyanoacrylates, polycaprolactone dimethyl acrylates, poly-b-maleic acid
  • Polycaprolactone butyl acrylates multiblock polymers such as e.g. from oligocaprolactone diols and oligodioxanonediols, polyetherester multiblock polymers such as e.g.
  • Polyhydroxypentanoic acid Polyanhydrides, polyethylene oxide-propylene oxide, soft polyurethanes, polyurethanes with amino acid residues in the backbone, polyether esters such as polyethylene oxide, polyalkene oxalates, polyorthoesters and their copolymers, carrageenans, fibrinogen, starch, collagen, protein-based polymers, polyamino acids, synthetic polyamino acids, zein , modified zein, polyhydroxyalkanoates, pectinic acid, actinic acid, modified and unmodified fibrin and casein, carboxymethylsulfate, albumin, further hyaluronic acid, heparan sulfate, heparin, chondroitin sulfate, dextran, b-cyclodextrins, and copolymers with PEG and polypropylene glycol, gum arabic, guar, gelatin , Collagen Collagen-N-hydroxysuccinimide, modifications and
  • such a bioresorbable stent of metal or organic polymers is now crimped onto a coated catheter balloon.
  • the bioresorbable variant has the advantage that the stent completely dissolves after a period of a few weeks to about 18 months and thus no permanent foreign body remains in the patient, which could cause chronic inflammation.
  • About the coated catheter balloon enough drug is applied during dilatation that the stent can first grow in a controlled manner and after ingrowth only begins to decompose in such a way that no fragments can be washed away through the vessel or through the bloodstream.
  • the drug or drug combination can be applied to the stent surface as a pure drug layer or embedded in a non-polymeric matrix such as a contrast agent, contrast agent mixture or contrast agent analog on the stent surface or in a polymeric carrier such as one of the above biodegradable polymers are located on the stent surface and / or incorporated or incorporated into the biodegradable stent material itself.
  • a non-polymeric matrix such as a contrast agent, contrast agent mixture or contrast agent analog on the stent surface or in a polymeric carrier such as one of the above biodegradable polymers are located on the stent surface and / or incorporated or incorporated into the biodegradable stent material itself.
  • the biodegradable stent material ie into the stent itself, and additionally to coat this stent with an active substance or to coat it with a polymeric or non-polymeric carrier containing one or more active substances.
  • the stent or the drug-containing layer can in turn be provided with a biodegradable barrier layer or haemocompatible layer, so that two-layer systems or multi-layer systems represent possible embodiments.
  • combinations of active ingredients are also conceivable in that an active substance combination is applied to the stent or to the stent, or a combination of active substances is formed by virtue of the fact that another active substance is present in the stent than on the stent.
  • a drug combination may also be achieved by having the same drug on the stent and the catheter balloon in different concentrations, for example in a cytotoxic dose on the catheter balloon and a cytostatic dose on and / or in the stent.
  • an active substance is preferably applied, which unfolds its effect within a few hours or days after dilatation, wherein a second active substance is preferably applied or introduced on the stent or in the biodegradable stent in a different concentration, which in particular deploys a long-term effect and released during the time of biodegradation of the stent.
  • a cytotoxic dose of an active substance is present on the catheter balloon and a cytostatic dose of the same or of another active substance is contained on the stent and / or in the biodegradable stent.
  • a particularly preferred embodiment contains paclitaxel on the catheter balloon in a cytotoxic dose and in a polymeric coating on a metal stent or in a biodegradable coating on the bioresorbable stent in a cytostatic concentration.
  • Another particularly preferred embodiment is a combination of paclitaxel in a cytotoxic or a cytostatic dose on the catheter balloon and a preferably cytostatic dose of rapamycin on or in the biodegradable stent.
  • the embodiments of the present invention are useful for spontaneously releasing (spo ⁇ tanrelease) relatively much drug because the stent strut interstices and the interstices between the stent inner surface and the surface of the catheter balloon serve as a drug reservoir, i. from the catheter balloon surface sufficient drug is applied during dilation between the stent struts and preferably in the beyond the stent ends areas of the vessel wall to successfully prevent restenosis.
  • a coating solution for the catheter balloon and the stent are solutions of eg Paclitaxel in dimethyl sulfoxide (DMSO) or methanol / ethanol mixtures or of rapamycin in ethyl acetate or in ethanol.
  • DMSO dimethyl sulfoxide
  • rapamycin rapamycin in ethyl acetate or in ethanol.
  • other agents may be used, especially those listed below.
  • non-polymeric ones are more suitable
  • Carriers such as contrast agents or contrast agent analogues as well as biocompatible organic substances such as amino acids, sugars,
  • Vitamins, saccharides and the like for the coating of the catheter balloon.
  • Physiologically acceptable salts can also be used as matrix for incorporation of the
  • Drug can be used on the catheter balloon.
  • the balloon is coated over the surface covered by the stent.
  • the coated area of the balloon beyond the end of the stent is not more than 20% of the total length of the stent, preferably not more than 15% and most preferably not more than 10% of the total length of the stent.
  • a full-area coating of the catheter balloon is advantageous, i.
  • the catheter balloon is provided over its entire surface with a coating.
  • the coating of the catheter balloon may be further designed so that the coating with active ingredient is not uniform, but one uses a gradient, i. E. a concentration gradient of drug is generated on the balloon surface. For example, in the center of the catheter balloon, a greater concentration of drug may be applied or at one or both ends of the catheter balloon or in the middle and at one or both ends.
  • the at least one antiproliferative, antiinflammatory, antiangiogenic, cytostatic, cytotoxic, antithrombotic, antiinflammatory and / or antiestrogenic active agent is preferably present on the catheter balloon either as a pure active ingredient layer in dried form or incorporated into a polymeric or non-polymeric matrix, the non-polymeric Matrix is preferred.
  • contrast agents and contrast agent analogues can be used as the non-polymeric matrix or coating or carrier.
  • Contrast agents and contrast agent analogues have the property that they are non-polymeric compounds, which in addition usually already have clinical approval, are physiologically largely harmless and can be used if polymeric carrier systems and carrier substances are to be avoided.
  • Contrast agent analogs are defined as contrast agent-like substances which have the properties of contrast agents, i. can be visualized by applicable in an operation imaging techniques.
  • Barium, iodine, manganese, iron, lanthanum, cerium, praseodymium, neodymium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium and / or lutetium are preferred as contrast agents and / or contrast agents / or complexed form.
  • contrast agents are to be distinguished for various imaging methods.
  • contrast agents used in X-ray examinations X-ray contrast agents
  • contrast agents for magnetic resonance imaging MR contrast agents
  • X-ray contrast agents are substances that either lead to an increased absorption of incident X-rays to the surrounding structure (so-called positive contrast agent) or incidental X-rays increasingly unhindered pass (so-called negative contrast agent).
  • Preferred X-ray contrast agents are those used for joint imaging (arthrography) and CT (computed tomography).
  • CT computed tomography
  • the computer tomograph is a device for taking sectional images of the human body by means of X-rays.
  • X-radiation according to the invention can also be used for detection in the imaging method, this radiation is not preferred because of its harmfulness. It is preferred if the incident radiation is non-ionizing radiation.
  • X-rays, computed tomography (CT), magnetic resonance imaging and Magnetic Resonance Imaging (MRI) are preferred, with magnetic resonance imaging and magnetic resonance imaging (MRI) are preferred.
  • iodine-containing contrast agents are preferred, which are used in angiography and venography (CT) and CT (computed tomography).
  • iodine Lipiodol ® an iodinated oleum papaveris, a poppy oil.
  • Gastrografin ® and Gastrolux ® the mother substance of the iodinated contrast agent diatrizoate in the form of sodium and meglumine salts are commercially available.
  • gadolinium-containing or superparamagnetic iron oxide particles and ferrimagnetic or ferromagnetic iron particles such as nanoparticles are preferred.
  • Another class of preferred contrast agents are the paramagnetic contrast agents, which usually contain a lanthanide.
  • the paramagnetic substances that have unpaired electrons include, for example, the gadolinium (Gd 3+ ), which has a total of seven unpaired electrons. Also included in this group are europium (Eu 2+ , Eu 3+ ), dysprosium (Dy 3+ ) and holmium (Ho 3+ ). These lanthanides can also be produced in chelated form using, for example, hemoglobin, chlorophyll, Polyazaklaren, polycarboxylic acids and in particular EDTA, DTPA, DMSA, DMPS and DOTA can be used as a chelating agent.
  • gadolinium-containing contrast agents examples include gadolinium-diethylenetriaminepentaacetic acid
  • Gadopentetic acid GaDPTA
  • paramagnetic substances that can be used according to the invention are ions of so-called transition metals such as copper (Cu 2+ ), nickel (Ni 2+ ), chromium (Cr 2+ , Cr 3+ ), manganese (Mn 2+ , Mn 3+ ) and iron (Fe 2 + , Fe 3+ ). These ions can also be used in chelated form.
  • such coatings also have the advantage of making the catheter balloon more visible in the imaging processes, i. to make detectable.
  • contrast agents and contrast agent analogues are used, for example, to take up the active substance (s) and in particular paclitaxel or rapamycin.
  • the catheter balloon can be coated or the folds of a catheter balloon filled.
  • such a liquid solution may leak from the interior of the catheter balloon through a plurality of micropores and / or nanopores, preferably under pressure and assist in the detachment of a coating located on the balloon surface.
  • contrast agent and active substance in particular paclitaxel and rapamycin
  • paclitaxel and rapamycin are particularly well suited to microrough surface or in vitro Microcavities bring in, whereby such a coating must be coated with a barrier layer which usually bursts or ruptures during the dilation and until then protects the contrast agent-drug mixture from premature removal and premature dissolution.
  • this composition is introduced into or under the folds of pleated balloons or applied to the surface of the catheter balloon, which may have textures or microneedles or other fillable spaces, and thereafter preferably coated with a barrier layer.
  • a barrier layer a polymeric layer can be used, as disclosed, for example, in WO 2004/052420 A2 or EP 1150622 A1.
  • Such a barrier layer may consist of polylactides, polyglycolides, polyanhydrides, polyphosphazenes, polyorthoesters, polysaccharides, polynucleotides, polypeptides, polyolefins, vinyl chloride polymers, fluorine-containing polymers, teflon, polyvinyl acetates, polyvinyl alcohols, polyvinyl acetals, polyacrylates, polymethacrylates, polystyrene, polyamides, polyimides, polyacetals, Polycarbonates, polyesters, polyurethanes, polyisocyanates, polysilicones and copolymers and mixtures of these polymers.
  • the coating of the catheter balloon and stent is done separately, i. the catheter balloon is coated without a crimped stent applied and the stent is also coated alone.
  • the coating method the usual spraying, dipping, brushing, plasma deposition and pipetting methods can be used.
  • the crimped stent expandable catheter catheter system of the present invention may be obtained by: a) providing a balloon for a dilatation catheter, b) providing a stent, c) separately coating the stent and the catheter balloon with one another
  • the catheter balloon and stent are coated separately, with a biodegradable coating with an active agent preferably being applied to the stent and preferably the same or different active agent being applied to the catheter balloon in pure form or in a non-polymeric carrier system such as a contrast agent ,
  • the coating of stents can also be provided with a barrier layer, which preferably bursts during dilation, so that the active ingredient can be eluted or released from the underlying layer.
  • the stent is crimped onto the catheter balloon. Thereafter, the sterilization and packaging.
  • the present invention accordingly also relates to expandable systems obtainable by such a process.
  • antiproliferative, anti-inflammatory, anti-angiogenic, cytostatic, cytotoxic, antithrombotic, anti-inflammatory and / or anti-restenotic agents for example, those listed below may be selected: abciximab, acemetacin, acetylvismion B, aclarubicin, ademetionin, adriamycin, aescin, afromosone, akagerin, aldesleukin, amidorone , Aminoglutethemide, amsacrine, anakinra, anastrozole, anemonin, anopterin, antifungals, antithrombotics, apocymarin, argatroban, aristolactam-all, aristolochic acid, ascomycin, asparaginase, aspirin, atorvastatin, auranofin, azathioprine, azithromycin, baccatin, bafilomycin, basiliximab, bendamustine
  • Platelet membrane receptor, factor X a -nhibitor antibody, heparin, hirudin, r-hirudin, PPACK, protamine, prourokinase, streptokinase, warfarin, urokinase, vasodilators such as dipyramidol, trapidil, nitroprussides, PDGF antagonists such as triazolopyrimidine and seramin, ACE inhibitors such as Captopril, cilazapril, lisinopril, enalapril, losartan, thioprotease inhibitors, prostacyclin, vapiprost, interferon ⁇ , ⁇ and Y, histamine antagonists, serotonin blockers, apoptosis inhibitors, apoptosis regulators such as p65, NF-kB or Bcl-xL antisense oligonucleotides, halofuginone, n
  • the active ingredient can be applied in pure form or together with a polymer or a non-polymeric carrier.
  • a polymer or a non-polymeric carrier preferably dipping or spraying methods are used.
  • Antirestenosewirkstoff be embedded in a polymer matrix or located under or on a polymer matrix.
  • another polymeric biostable or biodegradable layer may be in addition to the polymer matrix on the stent.
  • this layer may contain another anti-proliferative, anti-inflammatory, anti-angiogenic, cytostatic, cytotoxic, antithrombotic, anti-inflammatory and / or anti-restenotic agent, which may be the same or different from the active ingredient in the polymer matrix.
  • biostable or biodegradable polymers and / or polymers for the polymer matrix polyvalerolactones, poly- ⁇ -decalactones, polylactic acid, polyglycolic acid polylactides, polyglycolides, copolymers of polylactides and polyglycolides, poly- ⁇ -caprolactone, polyhydroxybutyric acid, polyhydroxybutyrates, polyhydroxyvalerates .
  • Polyhydroxybutyrate-co-valerates poly (1,4-dioxane-2,3-diones), poly (1,3-dioxan-2-ones), poly-para-dioxanones, polyanhydrides, polymaleic anhydrides, polyhydroxymethacrylates, fibrin, polycyanoacrylates,
  • Polyvinyl alcohols polyester amides, glycolated polyesters, polyphosphoesters, polyphosphazenes, poly [p-carboxyphenoxy) propane], polyhydroxypentanoic acid, polyanhydrides, polyethylene oxide propylene oxide, soft polyurethanes, polyurethanes with amino acid residues in the backbone, polyether esters such as polyethylene oxide, polyalkene oxalates, polyorthoesters and their copolymers, lipids, carrageenans , Fibrinogen, starch, collagen, protein-based polymers, polyamino acids, synthetic polyamino acids, zein, polyhydroxyalkanoates, pectinic acid, actinic acid, carboxymethylsulfate, albumin, hyaluronic acid, chitosan and its derivatives, heparan sulfates and its derivatives, heparins, chondroitin sulfate, dextran, ⁇ -cyclodextrins
  • the expandable systems according to the invention are outstandingly suitable for the prophylaxis, prevention or reduction of restenosis.
  • Example 1 A commercially available catheter with a polyamide catheter balloon is spray-coated with a solution of paclitaxel in DMSO.
  • the coating is dried after each spray pass and the spray coating is repeated three times.
  • a commercially available cobalt-chromium stent is provided with a carbon layer and then coated with a polymeric coating of a polylactide-polyglycolide.
  • the polymeric biodegradable coating preferably contains the drug rapamycin in a cytostatic concentration.
  • the coated stent is now crimped onto the coated catheter balloon.
  • a commercially available catheter with a polyamide catheter balloon is dip coated with a preferably cytotoxic solution of paclitaxel in DMSO.
  • the coating is dried after each dipping process and the dipping process is repeated twice.
  • a commercially available vanadium stent is coated with a polymeric coating of a polyurethane containing paclitaxel, preferably in a cytostatic concentration.
  • the coated stent is now crimped onto the coated catheter balloon.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne un système expansible composé d'un ballonnet de cathéter muni d'un stent contracté, ledit système combinant une cinétique de libération rapide de principe actif avec une cinétique de libération lente d'un second principe actif, étant donné que le ballonnet de cathéter est recouvert d'un premier principe actif convenant à une libération rapide et le stent est recouvert d'un second principe actif convenant à une libération plus lente. Dans un mode de réalisation préféré, le ballonnet de cathéter est recouvert d'une quantité zytotoxique d'un premier principe actif et le stent est recouvert d'une quantité zytotoxique d'un second principe actif.
EP08706903A 2007-02-21 2008-02-20 Système expansible muni d'un revêtement Withdrawn EP2125062A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007008479A DE102007008479A1 (de) 2007-02-21 2007-02-21 Beschichtetes Expandierbares System
US90329807P 2007-02-26 2007-02-26
PCT/DE2008/000301 WO2008101486A2 (fr) 2007-02-21 2008-02-20 Système expansible muni d'un revêtement

Publications (1)

Publication Number Publication Date
EP2125062A2 true EP2125062A2 (fr) 2009-12-02

Family

ID=39669914

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08706903A Withdrawn EP2125062A2 (fr) 2007-02-21 2008-02-20 Système expansible muni d'un revêtement

Country Status (6)

Country Link
US (1) US20100076542A1 (fr)
EP (1) EP2125062A2 (fr)
BR (1) BRPI0807618A2 (fr)
DE (1) DE102007008479A1 (fr)
RU (1) RU2009135014A (fr)
WO (1) WO2008101486A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110551120A (zh) * 2018-06-04 2019-12-10 首都医科大学 6-氨基酰氨基正己酰咔啉羧酸苄酯,其制备,活性和应用
US12084593B2 (en) 2018-12-19 2024-09-10 Ppg Industries Ohio, Inc. Sprayable silicone polymer dispersion

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306166B1 (en) * 1997-08-13 2001-10-23 Scimed Life Systems, Inc. Loading and release of water-insoluble drugs
EP3150236B1 (fr) * 2006-02-09 2018-12-26 B. Braun Melsungen AG Procédé de revêtement de ballonnet repliable
WO2008086794A2 (fr) 2007-01-21 2008-07-24 Hemoteq Ag Produit médical destiné à traiter des occlusions de voies corporelles et à prévenir les risques de nouvelle formation de l'occlusion
ES2530862T3 (es) * 2007-02-07 2015-03-06 Cook Medical Technologies Llc Revestimientos de dispositivos médicos para liberar un agente terapéutico a diferentes velocidades
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
US8858995B2 (en) 2008-03-10 2014-10-14 University Of Louisville Research Foundation, Inc. Methods and compositions for controlled delivery of phytochemical agents
US9114125B2 (en) 2008-04-11 2015-08-25 Celonova Biosciences, Inc. Drug eluting expandable devices
DE102008040143A1 (de) * 2008-07-03 2010-01-07 Biotronik Vi Patent Ag Degradierbarer Magnesium-Stent oder Medizinprodukt mit Beschichtung umfassend Dipyridamol
DE102008049469B3 (de) * 2008-09-29 2010-05-12 Siemens Aktiengesellschaft Verfahren zur Überwachung eines Stents
DE102008043277A1 (de) * 2008-10-29 2010-05-06 Biotronik Vi Patent Ag Implantat aus einer biokorrodierbaren Eisen- oder Magnesiumlegierung
DE102009005792B4 (de) * 2009-01-22 2019-06-19 Feg Textiltechnik Forschungs- Und Entwicklungsgesellschaft Mbh Medizinisches Implantat mit Oberflächenbeschichtung
ES2550634T3 (es) 2009-07-10 2015-11-11 Boston Scientific Scimed, Inc. Uso de nanocristales para un balón de suministro de fármaco
US10080821B2 (en) 2009-07-17 2018-09-25 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
DE102010022588A1 (de) * 2010-05-27 2011-12-01 Hemoteq Ag Ballonkatheter mit einer partikelfrei Wirkstoff-abgebenden Beschichtung
ES2522265T3 (es) 2010-06-21 2014-11-14 Zorion Medical, Inc. Implantes bioabsorbibles
WO2012031236A1 (fr) 2010-09-02 2012-03-08 Boston Scientific Scimed, Inc. Procédé d'enrobage de ballonnets d'administration de médicaments utilisant une mémoire d'enveloppe induite par la chaleur
WO2012039884A1 (fr) 2010-09-23 2012-03-29 Boston Scientific Scimed, Inc. Ballonnet revêtu de médicament doté d'un revêtement transférable
US8986369B2 (en) 2010-12-01 2015-03-24 Zorion Medical, Inc. Magnesium-based absorbable implants
US8669360B2 (en) 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (fr) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Dispositif médical comprenant un revêtement médicamenteux cristallin
WO2013148682A1 (fr) * 2012-03-26 2013-10-03 University Of Louisville Research Foundation, Inc. Procédés et compositions pour l'administration contrôlée d'agents phytochimiques
TWI478943B (zh) * 2012-12-27 2015-04-01 Ind Tech Res Inst 高分子組成物用於製備具有抑制基質金屬蛋白酶之活性的功效的醫療器材或抑制劑的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19539449A1 (de) 1995-10-24 1997-04-30 Biotronik Mess & Therapieg Verfahren zur Herstellung intraluminaler Stents aus bioresorbierbarem Polymermaterial
US6245537B1 (en) 1997-05-12 2001-06-12 Metabolix, Inc. Removing endotoxin with an oxdizing agent from polyhydroxyalkanoates produced by fermentation
US6245103B1 (en) 1997-08-01 2001-06-12 Schneider (Usa) Inc Bioabsorbable self-expanding stent
EP0966979B1 (fr) 1998-06-25 2006-03-08 Biotronik AG Support pour la paroi des vaisseaux implantable et biodégradable, notamment un extenseur coronaire
DE19856983A1 (de) 1998-06-25 1999-12-30 Biotronik Mess & Therapieg Implantierbare, bioresorbierbare Gefäßwandstütze, insbesondere Koronarstent
US6419692B1 (en) * 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
ES2295021T3 (es) 1999-03-25 2008-04-16 Metabolix, Inc. Utilizacion y aplicaciones medicas de polimeros de poli(hidroxialcanoatos).
US6368346B1 (en) 1999-06-03 2002-04-09 American Medical Systems, Inc. Bioresorbable stent
WO2002066095A2 (fr) * 2001-02-16 2002-08-29 Cordis Corporation Procede associe a un systeme de pose d'endoprothese a sonde a ballonnet comportant des cretes
US6585755B2 (en) * 2001-06-29 2003-07-01 Advanced Cardiovascular Polymeric stent suitable for imaging by MRI and fluoroscopy
AU2003256540B2 (en) * 2002-07-12 2008-12-11 Cook Medical Technologies Llc Coated medical device
DE10244847A1 (de) * 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
DE10253634A1 (de) 2002-11-13 2004-05-27 Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin Endoprothese
US20040111144A1 (en) 2002-12-06 2004-06-10 Lawin Laurie R. Barriers for polymeric coatings
EP1663343B8 (fr) * 2003-09-15 2019-12-04 Atrium Medical Corporation Application d'une substance therapeutique sur une zone tissulaire au moyen d'un dispositif medical extensible
EP2301619B1 (fr) * 2004-03-19 2017-05-10 Abbott Laboratories Administration de médicaments multiples à partir d'un ballonnet et d'une prothèse
DE102005039126A1 (de) * 2005-08-18 2007-02-22 Lothar Sellin Parylene-beschichtete expandierbare Vorrichtung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008101486A2 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110551120A (zh) * 2018-06-04 2019-12-10 首都医科大学 6-氨基酰氨基正己酰咔啉羧酸苄酯,其制备,活性和应用
CN110551120B (zh) * 2018-06-04 2020-10-20 首都医科大学 6-氨基酰氨基正己酰咔啉羧酸苄酯,其制备,活性和应用
US12084593B2 (en) 2018-12-19 2024-09-10 Ppg Industries Ohio, Inc. Sprayable silicone polymer dispersion

Also Published As

Publication number Publication date
RU2009135014A (ru) 2011-03-27
WO2008101486A3 (fr) 2009-11-05
WO2008101486A2 (fr) 2008-08-28
DE102007008479A1 (de) 2008-09-04
BRPI0807618A2 (pt) 2014-07-22
US20100076542A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
EP2125062A2 (fr) Système expansible muni d'un revêtement
EP2114481B1 (fr) Endoprothèse vasculaire biodégradable
EP2125060B1 (fr) Procédé de charge de surfaces structurées
EP2182896B1 (fr) Cathéter à ballonnet pourvu d'une protection empêchant un déploiement prématuré
EP2744532B1 (fr) Endoprotheses resorbables contenant un alliage de magnesium
DE102005018356B4 (de) Resorbierbare Implantate
EP2046410B1 (fr) Fabrication et utilisation d'articles médicaux à libération de principes actifs pour maintenir ouverts en permanence des vaisseaux sanguins et procédés associés
EP1435877B1 (fr) Revetement de stents empechant la restenose
DE102005021622B4 (de) Ganzflächige Beschichtung von Stents
EP2125063A2 (fr) Stent métallique biorésorbable à résorption régulée
EP3562526A1 (fr) Endoprothèse en alliage de magnésium biodégradable recouverte d'un revêtement en fluorure de magnésium et d'un revêtement organique
EP2269664A2 (fr) Produit médical pour le traitement de fermetures de passages de corps et de prévention des menaces de refermetures
EP2575917A2 (fr) Revêtement d'endoprothèses d'une couche de fils polymères entrelacés à mailles serrées
EP2233162A2 (fr) Implant médical destiné à la libération de médicaments ayant une surface poreuse
WO2014008875A1 (fr) Ballonnet de cathéter, procédé de fabrication d'un ballonnet de cathéter revêtu, et utilisation de la substance active pharmacologique
DE102007034350A1 (de) Biologisch abbaubare Gefäßstütze
DE102005039126A1 (de) Parylene-beschichtete expandierbare Vorrichtung
DE102004046244A1 (de) Beschichtetes Coronarstentsystem
DE202013002567U1 (de) NABP - Beschichtung
EP2213316A1 (fr) Dispositif expansible revêtu d'iode
DE102004048265A1 (de) Vorrichtung zur Gefäßaufweitung
DE102007010354A1 (de) Beschichtete expandierbare Vorrichtung
WO2012051992A2 (fr) Ballonnet de cathéter à dilatation radiale avec enveloppe textile
DE202011002929U1 (de) Stent zur Implantation in den menschlichen Körper
DE202011106744U1 (de) Bessere Bioverfügbarkeit von Shellac/Paclitaxel Beschichtungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090807

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

R17D Deferred search report published (corrected)

Effective date: 20091105

RIC1 Information provided on ipc code assigned before grant

Ipc: A61L 29/16 20060101AFI20091111BHEP

Ipc: A61L 31/10 20060101ALI20091111BHEP

Ipc: A61L 29/08 20060101ALI20091111BHEP

Ipc: A61L 31/16 20060101ALI20091111BHEP

17Q First examination report despatched

Effective date: 20100114

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140311